FDA Investigator Barbara L Rogolsky

Barbara L Rogolsky has inspections in 5 countries as of 11 Nov 2022. Barbara L Rogolsky has collaborated with a combinined 3242 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
27
Last Inspection Date:
11 Nov 2022
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, India, Israel, Japan
Co-Investigator(s):
Adaliz Santaliz Cruz, Adree N Anderson, Alan E Mehl, Alan M Barker, Amir A Abdalla, Amy E Devine, Anastasia M Shields, Angela E Glenn, Anthony R Bucks, Aref M El Demerdash, Ashley A Mutawakkil, Audrey N Vigil, Barbara I Rogolsky, Barbara J Ragolsky, Bichsa T Tran, Brenda C Hamilton, Brent M Dehaan, Brett R Havranek, Bridgette M Mattern, Brittany D Terhar, Bryan S Roddy, Bryce A Hammer, Candace S Tucker, Carl A Huffman, III, Carl J Montgomery, Carmen Y Fisher, Cheryl A Clausen, Chilton L Ng, Christopher S Keating, Cody D Rickman, Constantin Y Philopoulos, Cynthia C Smith, PhD, Cynthia L Evitt, Cynthia M Goudeau, Dana D Carter, SR DDS, Danial S Hutchison, Daniel J Roberts, Daniel R Hurt, Darrah, David J Eide, Dawn C Olenjack, Devaugh Edwards, Devaughn Edwards, Douglas M Monroe, Eric C Nielsen, Eric M Mueller, PharmD, Erika V Butler, Evelyne L Weaver, Farhana Khan, Gwyn D Dickinson, Gwyn G Dickinson, Helen Verdel, Heriberto Negron Rivera, James D Planchon, James I Giefer, Janete A Eaker, Jawaid Hamid, Jeannie M Vonderbrink, Jeffery A Hangartner, Jennifer Cahill, Jeremy W Rotton, Jessica L Peterson, Jill J Tillman, Joan M Nandrea, Joey V Quitania, Jogy George, John A Iwen, John A Marchin, Johnson, Johnsont, Jonathan R Campos, Jose Acruz Gonzalez, Jose E Melendez, DDC, Jose M Cayuela, Joseph R Lambert, Julianne C Mccullough, Julie N Vosilus, Kara L Cooper, Kara L Roden, Karen C Daugherty, Katherine Szestypalow, Kathleen B Swat, Kellia N Hicks, Kelly A Lynch, Kenneth H Williams, Kenneth Nieves, Kenneth R Merritt, LCDR Matthew J Morrison, Leonard H Lavi, Libia M Lugo, Linda K Cline, Linda R Kuchenthal, Lisa L Flores, Lisa L Gilliam, Lori A Gioia, Luis A Dasta, Marcus F Yambot, Margaret M Annes, Marion D Wimberly, Jr, Mark S Ross, Martin J Kurek, Matthew A Walburger, Matthew B Casale, Matthew M Henciak, Matthew R Sleeter, Megan A Haggerty, Megan M Kirk, Meisha Waters, Melissa J Garcia, Michael A Charles, Michael A Feingold, Michael S Smoker, Michael Y Philopoulos, Michele L Chet, Michele L Obert, Michele Perry Williams, Minerva Rogers, Monica M Mcclure, Monique M Brooks, Muralidhara B Gavini, PhD, Nancy G Schmidt, Neal L Adams, Nicole J Conklin, Paige E Shelborne, Paige E Wilson, Pamela L Vega, Pankaj H Amin, Parul M Patel, Patricia H Dlugosz, Patrick L Wisor, Rachel Collen, Ralph A Erickson, Ralph H Vocque, Randy D Moore, Raymond Valdivia, Rebecca Rodriguez, Rita K Kabaso, Robert J Ham, Robert J Martin, Robin K Hatfield, Robin K Reel, Rozelle G Smith, Ruben C Ayala, PharmD, S Lori Brown, PhD MPH, Saleem A Akhtar, Samuel K Gibbons, Jr, Sarah E Morris, Shafiq S Ahadi, Shanna R Haden, Sharon K Thoma, PharmD, Sheri L Stephenson, Shirley J Berryman, Shirley J Burryman, Simone E Pitts, Sina Shojaee, State Agency, Steven D Kehoe, Steven P Allen, Stroman, Susanna E Ford, Analyst, Suzanna E Ford, Tamara J Genetti, Tamara J Umscheid, Tammy L Smith, Tara L Breckenridge, Tara L Greene, Tara L King, Tonya R Johnson, Torrance J Slayton, Torrey M Ward, Tristian E Strait, Vani Mathur Richards, Verlinda A Narcisse, Vickie J Kanion, Victoria A Wagoner, Vlada Matusovsky, Walsworth, Warren J Lopicka, Wayne D Mcgrath, William C Corley, Xiaohan Cai, PhD, Yiyue Zhang (nmi), PhD, Yumi J Hiramine, Zachary A Bogorad

Barbara L Rogolsky's Documents

Publish Date Document Type Title
August, 2003 FDA 483 Ioditech Inc - Form 483, 2003-08-05
November, 2002 FDA 483 CIPLA LIMITED - Form 483, 2002-11-14
April, 2002 EIR Kyorin Pharmaceutical Group Facilities Co., Ltd. - EIR, 2002-04-11
April, 2003 FDA 483 Response Sanofi - Aventis US LLC - Form 483R, 2003-04-29
June, 2003 EIR Strategic Veterinary Pharmaceuticals, Inc. - EIR, 2003-06-27
November, 2002 EIR CIPLA LIMITED - EIR, 2003-01-17
April, 2001 FDA 483 Response Cambrex Charles City, Inc - Form 483R, 2001-04-26
August, 2000 EIR Zoetis Inc - EIR, 2000-08-21
April, 2004 FDA 483 Wilbur-Ellis Nutrition, LLC - Form 483, 2004-04-29
June, 2002 FDA 483 Nostrum Laboratories, Inc. - Form 483, 2002-06-18
March, 2000 FDA 483 Nesher Pharmaceuticals (USA) LLC - Form 483, 2000-03-03
November, 2002 FDA 483 Response USV Private Limited - Form 483R, 2002-11-22
April, 2003 EIR Sanofi - Aventis US LLC - EIR, 2003-04-09
April, 2002 FDA 483 Kyorin Pharmaceutical Group Facilities Co., Ltd. - Form 483, 2002-04-11
April, 2001 FDA 483 Cambrex Charles City, Inc - Form 483, 2001-04-13
November, 2002 FDA 483 USV Limited - Form 483, 2002-11-09
April, 2004 EIR Wilbur-Ellis Nutrition, LLC - EIR, 2004-04-29
November, 2002 EIR USV Private Limited - EIR, 2008-03-21
May, 2003 EIR Zoetis Inc - EIR, 2003-05-09
November, 2002 FDA 483 Response CIPLA LIMITED - Form 483R, 2002-11-21
November, 2002 FDA 483 Response CIPLA LIMITED - Form 483R, 2002-12-02
November, 2002 EIR CIPLA LIMITED - EIR, 2003-01-17
April, 2003 FDA 483 Sanofi - Aventis US LLC - Form 483, 2003-04-09
March, 2000 FDA 483 Response Nesher Pharmaceuticals (USA) LLC - Form 483R, 2000-03-16
August, 2000 FDA 483 Zoetis Inc - Form 483, 2000-08-21

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more